MedPath

Ultragenyx's UX111 Gene Therapy Shows Promise in Sanfilippo Syndrome Type A

• UX111 (rebisufligene etisparvovec) is an investigational gene therapy for Sanfilippo syndrome type A (MPS IIIA), a rare and fatal lysosomal storage disease. • The therapy uses an AAV9 vector to deliver a functional copy of the SGSH gene, addressing the underlying enzyme deficiency that causes heparan sulfate accumulation. • UX111 has received multiple designations, including Regenerative Medicine Advanced Therapy and Orphan Drug status, highlighting its potential impact on this unmet medical need.

Ultragenyx Pharmaceutical is developing UX111 (rebisufligene etisparvovec), a novel in vivo gene therapy, as a potential treatment for Sanfilippo syndrome type A (MPS IIIA). This rare, fatal lysosomal storage disease, also known as mucopolysaccharidosis type IIIA, is characterized by rapid neurodegeneration due to the accumulation of heparan sulfate in the central nervous system (CNS). With no approved treatments currently available, UX111 represents a significant advancement in addressing this unmet medical need.

Understanding Sanfilippo Syndrome Type A

MPS IIIA affects an estimated 3,000 to 5,000 patients in commercially accessible regions and typically results in a median life expectancy of just 15 years. Children with MPS IIIA experience global developmental delays, progressive cognitive and language decline, behavioral abnormalities, and ultimately, early death. The disease is caused by biallelic pathogenic variants in the N-sulfoglucosamine sulfohydrolase (SGSH) gene, leading to a deficiency in the sulfamidase enzyme. This enzyme is crucial for breaking down heparan sulfate, a glycosaminoglycan. The deficiency results in the accumulation of heparan sulfate within cells throughout the body, leading to the severe neurodegeneration associated with the disorder.

UX111: A Gene Therapy Approach

UX111 is designed as a one-time intravenous infusion that utilizes a self-complementary AAV9 vector to deliver a functional copy of the SGSH gene directly to cells. By addressing the underlying sulfamidase enzyme deficiency, UX111 aims to reduce the abnormal accumulation of heparan sulfate in the brain, thereby mitigating progressive cell damage and neurodegeneration. The therapy is currently under evaluation in the pivotal Transpher A trial.

Regulatory Designations

The UX111 program has received several important designations that underscore its potential. In the United States, it has been granted Regenerative Medicine Advanced Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug designations. In the European Union, UX111 holds PRIME and Orphan Drug designations. These designations are intended to accelerate the development and review of promising therapies for serious or life-threatening conditions.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Ultragenyx Doses First Patient in Phase 3 Aspire Study of GTX-102 for Angelman Syndrome

Ultragenyx has initiated the Phase 3 Aspire study to evaluate GTX-102 for Angelman syndrome, a rare neurogenetic disorder.
The Aspire study will enroll 120 children aged 4-17 with Angelman syndrome, assessing cognitive and motor function improvements.

Ultragenyx's UX111 Gene Therapy for Sanfilippo Syndrome Type A Receives FDA Priority Review

The FDA has granted priority review to Ultragenyx's Biologics License Application (BLA) for UX111, a gene therapy for Sanfilippo syndrome type A (MPS IIIA).
The FDA's decision is expected by August 18, 2025, and the agency is not planning an advisory committee meeting for this application.

Ultragenyx's GTX-102 Shows Promise in Angelman Syndrome Phase 1/2 Trial

Ultragenyx presented positive Phase 1/2 data for GTX-102, an antisense oligonucleotide targeting Angelman syndrome, at the FAST Global Science Summit.
Patients in the Dose Expansion Cohorts demonstrated continued improvement across multiple domains at Week 48, with a mean change in Bayley-4 Cognition GSV score of +6.7.

Ultragenyx's Setrusumab Receives FDA Breakthrough Therapy Designation for Osteogenesis Imperfecta

Ultragenyx's setrusumab (UX143) has been granted Breakthrough Therapy Designation by the FDA to reduce fracture risk in osteogenesis imperfecta (OI) patients.
The FDA's decision was based on positive data from the Phase 2 Orbit study and Phase 2b ASTEROID study, demonstrating a significant reduction in fracture rates.

Gene Editing Shows Promise for Usher Syndrome Treatment

Researchers are exploring gene editing techniques to address the underlying genetic mutations in Usher syndrome, a rare disorder causing hearing and vision loss.
An exon skipping strategy targeting the Ush2A gene, responsible for the most common form of Usher syndrome, has shown potential in preclinical studies.

RGX-121 Gene Therapy Shows Sustained Efficacy in Hunter Syndrome Trial

RGX-121 gene therapy demonstrates an 85% median reduction in cerebrospinal fluid levels of heparan sulfate D2S6, a key biomarker in Hunter syndrome.
The CAMPSIITE trial data supports RGX-121 as a potential first gene therapy for Hunter syndrome, with sustained effects observed for up to two years.

Ultragenyx to Pursue Accelerated Approval for UX111 Gene Therapy in MPSIIIA

Ultragenyx plans to seek accelerated approval for UX111 (ABO-102), an AAV-based gene therapy, for mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome.
The FDA has aligned with Ultragenyx on using cerebral spinal fluid (CSF) heparan sulfate (HS) as a surrogate endpoint for accelerated approval.

Spinogenix Receives FDA Orphan Drug Designation for SPG601 to Treat Fragile X Syndrome

Spinogenix, Inc. has been granted Orphan Drug Designation by the U.S. FDA for SPG601, a novel treatment for Fragile X syndrome (FXS), highlighting the urgent need for new therapies. FXS, a leading cause of inherited intellectual disability and autism, lacks FDA-approved treatments. SPG601 aims to address core symptoms by modulating BK channels to restore synaptic function.

Two Major Breakthroughs in Fragile X Syndrome Treatments

Recent advancements in Fragile X Syndrome (FXS) treatments include Spinogenix's FDA approval for a Phase II clinical trial of SPG601 and the European Commission granting orphan drug status to Shionogi’s zatolmilast. These developments aim to address the significant unmet need for effective treatments in FXS, a condition causing developmental problems and cognitive impairment.

Ultragenyx's UX111 Gene Therapy Shows Sustained Efficacy in MPS IIIA Patients

UX111, an AAV9-based gene therapy, demonstrates rapid and sustained reduction of cerebrospinal fluid biomarker levels in MPS IIIA patients treated early.
A phase 1/2/3 clinical trial (Transpher A) showed dose-dependent efficacy, with the highest dose cohort (3 x 10^13 vg/kg) exhibiting the most significant biomarker reduction.

Reference News

[1]
UX111 for Sanfilippo syndrome type A (MPS IIIA)—Ultragenyx
ultragenyx.com · Oct 14, 2024

Sanfilippo syndrome type A (MPS IIIA) is a fatal CNS disorder caused by heparan sulfate accumulation due to SGSH gene mu...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy